VaxAlta is currently developing several glycoconjugate vaccines that target bacterial pathogens that impact animal health and human food safety (see our list of vaccines in the pipeline below).

VaxAlta also provides contract services to clients applying our proprietary platform technology toward the development of novel glycoconjugate vaccines against any pathogen (bacteria, virus, parasite, etc) where there is a unique glycan to target.

During our glycoconjugate vaccine workflow, VaxAlta also develops testing platforms for quality control that are available to our clients. This includes antibodies specific for the glycan antigen which can be used in diagnostic platforms.


Alberta vaccine research receives another booster - VaxAlta partners with Scandinavian Biopharma (December 21, 2021):

A paper describing progress toward the development of an effective Campylobacter jejuni vaccine for poultry is published November 16, 2021. Frontiers in Microbiology, special edition on Campylobacter-associated Food Safety, doi: 10.3389/fmicb.2021.734526

VaxAlta presenting at the 56th National Meeting on Poultry Health, Processing and Live Production, September 27-29, 2021, Ocean City, Maryland.

VaxAlta receives support from the Wellcome Trust for human enteric vaccine development (2021-2022).

Team members (Szymanski and Nothaft) receive the University of Alberta Innovation Award, May 20, 2021.

VaxAlta presenting at the 2021 Poultry Federation Food Safety Conference, March 29-31, 2021, Branson, Missouri.

VaxAlta presenting at the National Chicken Council Poultry Health and Growout Committee Meeting, September 28, 2020, Washington, D.C.

A paper describing the identification of a conserved Clostridium perfringens glycan antigen is published in the Journal of Biological Chemistry, May 18, 2020. https://

Alberta livestock vaccine research gets another booster, this time to develop a poultry vaccine against Clostridium perfringens using the VaxAlta glycoconjugate vaccine platform (April 15, 2020)

Szymanski elected into The American Academy of Microbiology, January 2020.

VaxAlta presenting at the Vaccines for Enteric Diseases Meeting, Oct 16 - 18, 2019 in Lausanne, Switzerland.

VaxAlta receives support from the Alberta Innovates Industry R&D Associates Program for Nothaft (2019-2020).

Szymanski receives the Peter Gallagher Memorial Glycomics Award for Contributions to Health and Medical Research, October 8, 2018, at the Institute for Glycomics, Griffith University, Gold Coast, Australia.

VaxAlta presenting at the 2nd GlycoCom Meeting, October 3-6, 2018 in Dubrovnik, Croatia.

VaxAlta moves into a new incubation facility at the University of Alberta and continues to invest in livestock vaccine research through a new collaboration with the Faculty of Medicine to advance our next generation of livestock vaccines (October 1, 2018).

Szymanski completes successful 5-year term as the Alberta Innovates Tier 1 Strategic Chair in Bacterial Glycomics (2013-2018).

VaxAlta receives support from the Industrial Research Assistance Program (IRAP) in 2018.

A paper describing our second generation Campylobacter jejuni vaccine is published in Applied and Environmental Microbiology, September 2017.

Szymanski is President of the Canadian Society of Microbiologists in 2017.

VaxAlta participates in the Society for Glycobiology meeting in New Orleans, Louisiana, November 19-22, 2016.

Our Chief Financial Officer, Jason Ding, was selected as one of Edmonton's Top 40 Under 40, November 2016.

VaxAlta team members (Christine Szymanski and Harald Nothaft) receive the TEC Edmonton Patent Award on October 19, 2016.

A paper describing our first generation Campylobacter jejuni vaccine is published in Scientific Reports, May 2016.

VaxAlta receives support from the Industrial Research Assistance Program (IRAP) and the Alberta Livestock and Meat Agency (ALMA) in 2016.

Szymanski is President of the Society for Glycobiology in 2016.

VaxAlta receives the TEC Edmonton Spin-off Award on October 8, 2015.

Sept 24, 2015: Alberta livestock vaccine research gets a $660,000 booster

VaxAlta presenting at GlycoCom 2015 in Banff, Alberta on May 3-5, 2015

Glycoconjugate vaccine pipeline:

Campylobacter species

Campylobacter jejuni (poultry)

Campylobacter fetus venerealis (cattle) and C. fetus fetus (sheep)

Streptococcus species

Streptococcus suis (pigs)

Streptococcus uberis (cattle)

Clostridium perfringens (poultry)

Salmonella species (poultry)

Avian Pathogenic Escherichia coli (poultry)

Get In Touch With Us

Christine Szymanski, Ph.D.
CEO VaxAlta Inc.
Harald Nothaft, Ph.D.
CSO VaxAlta Inc.